E Fund Management Co., Ltd. Mersana Therapeutics, Inc. Transaction History

E Fund Management Co., Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$2.16 - $5.94 $37,607 - $103,421	17,411 New	17,411 $78,000
Q2 2023 Aug 11, 2023	SELL	$3.08 - $9.55 $29,176 - $90,467	-9,473 Reduced 34.35%	18,105 $60,000
Q1 2023 May 11, 2023	BUY	$4.0 - $7.02 $22,936 - $40,252	5,734 Added 26.25%	27,578 $113,000
Q4 2022 Feb 14, 2023	BUY	$5.65 - $7.86 $40,391 - $56,191	7,149 Added 48.65%	21,844 $128,000
Q3 2022 Nov 14, 2022	BUY	$4.63 - $8.0 $68,037 - $117,560	14,695 New	14,695 $99,000
Q1 2021 May 12, 2021	BUY	$15.31 - $26.52 $117,932 - $204,283	7,703 New	7,703 $124,000

124

114M

73.5K

46.4K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $196M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on E Fund Management Co., Ltd. with notifications on news.